Loading Now

Latest

Anthem Biosciences Share Price: Listing Day Performance and Future Outlook

Anthem Biosciences IPO listing day share price analysis and future targets

Anthem Biosciences shares listed today with impressive market traction, reflecting investor confidence. Here’s a detailed analysis of its listing, market reaction, and share price target for 2025.

Table of Contents

Introduction

The long-awaited Anthem Biosciences IPO finally debuted on the stock exchanges today, July 21, 2025. Investors and market analysts closely tracked its performance, given the company’s strong presence in the biopharmaceutical sector and robust growth prospects. This article provides a comprehensive overview of Anthem Biosciences’ share price on listing day, its IPO details, future targets, and what it means for investors.


Anthem Biosciences IPO Listing: Key Highlights

Anthem Biosciences IPO Details

  • IPO Date: Closed recently with strong oversubscription

  • Issue Price: ₹436 per share

  • Listing Date: 21 July 2025

  • Listing Time: 10 AM onwards on NSE and BSE

Listing Performance

Anthem Biosciences shares listed at ₹718 on NSE, marking a 65% premium over the issue price, reflecting strong demand and positive market sentiment. On BSE, it opened at a similar price range, witnessing heavy trading volumes within the first hour.


Reasons Behind Strong Listing Gains

1. Strong Financials and Sector Leadership

Anthem Biosciences is one of India’s leading contract research and manufacturing organisations (CRMO) with consistent revenue growth, robust margins, and diversified client portfolios in domestic and international markets.

2. Robust GMP Standards and Expansion Plans

Their state-of-the-art GMP-certified facilities and plans to expand manufacturing capacities to meet global demand have attracted institutional investors, increasing IPO subscriptions manifold.

3. Positive GMP Trends Before Listing

The Grey Market Premium (GMP) for Anthem Biosciences IPO was ₹280-300 before listing day, signalling strong market expectations.


Anthem Biosciences Share Price Target 2025

Analysts’ Views

Leading brokerage firms project the following targets for Anthem Biosciences:

  • Short Term (3-6 months): ₹750-₹800, depending on quarterly performance and market conditions

  • Medium Term (FY2025 end): ₹850-₹900, if expansion plans materialise and revenue guidance is met

Key Growth Drivers

  • Increased CRMO demand globally

  • Expansion in biologics and speciality chemicals

  • Strategic collaborations for advanced research


Current Market Reaction

As of mid-day trade, Anthem Biosciences shares maintained their gains around ₹715-₹730 with heavy trading volumes. Analysts suggest cautious optimism, advising investors to track Q1 and Q2 results before adding more positions for long-term portfolios.


Challenges Ahead

Despite a stellar debut, the company faces challenges including:

  • Global regulatory compliance complexities

  • Rising input costs impacting margins

  • Competition from large Indian pharma manufacturers


Upcoming Results and Investor Watch Points

Investors should closely monitor:

  1. Q1 FY25 results expected in August

  2. Expansion timelines for their new manufacturing facilities

  3. Updates on international orders and regulatory approvals


FAQs

1. What was Anthem Biosciences IPO issue price?

The issue price was ₹436 per share.

2. At what price did Anthem Biosciences list today?

It listed at ₹718 on NSE, approximately 65% premium over its issue price.

3. What is the share price target for Anthem Biosciences for 2025?

Analysts expect the stock to reach ₹850-₹900 by FY2025 end, contingent on expansion and financial performance.

4. Should investors hold Anthem Biosciences shares?

Most brokerages recommend a hold strategy, tracking quarterly results before fresh buy decisions.


Helpful Resources


Latest Posts


Conclusion

Anthem Biosciences has made an impressive stock market debut, indicating robust investor faith in its growth trajectory. While analysts remain bullish for the medium term, investors should adopt a balanced approach, watching operational updates and sector trends to make informed decisions.

Post Comment